Skip to content

Low Glycemic Index Diets (With Pulses) in Type 2 Diabetes

Effect of Low Glycemic Index Diets (With Pulses) on Glucose Control in Non-Insulin Dependent Diabetics

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01063361
Enrollment
131
Registered
2010-02-05
Start date
2010-02-28
Completion date
2015-08-31
Last updated
2015-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Healthy individuals with type 2 diabetes will receive intensive counseling on food selection to improve glucose control using either high cereal fiber dietary strategies or low glycemic index foods emphasizing dried legumes and their products. The treatments will last 3 months with bloods taken for HbA1c, glucose and blood lipids. If the study shows a benefit for either or both diets, then use of high fiber and/or low glycemic index foods in the diet may provide another potential way to improve glucose control and lower cholesterol levels in non-insulin dependent diabetes.

Interventions

DIETARY_SUPPLEMENTLow glycemic index diet with pulses

Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.

DIETARY_SUPPLEMENTHigh Cereal Fibre

Subjects will be advised to follow a healthy high fibre diabetic diet.

Sponsors

Saskatchewan Pulse Growers
CollaboratorOTHER
Pulse Canada
CollaboratorOTHER
University of Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Men and women with type 2 diabetes who * are treated with oral hypoglycemic agents at a stable dose for at least 8 weeks * have a HbA1c in the range of 6.5% to 8.5% at screening and at the visit prior to randomization * have diabetes diagnosed \>6 months * have maintained stable weight for 2 months (within 3%) * have a valid OHIP card and a family physician * if prescribed lipid medication, have taken a stable dose for at least 2 weeks * if prescribed blood pressure medication, have taken a stable dose for at least 1 week * can keep written food records, with the use of a digital scale

Exclusion criteria

Individuals who * take insulin * take steroids * have GI disease (gastroparesis, celiac disease, ulcerative colitis, Crohn's Disease, IBS) * have had a major cardiovascular event (stroke or myocardial infarction) in the past 6 months * take warfarin (Coumadin) * have had major surgery in the past 6 months * have a major debilitating disorder * have clinically significant liver disease (AST or ALT \> 130 U/L), excluding NAFL or NASH * have hepatitis B or C * have renal failure (high creatinine \> 150 mmol/L) * have serum triglycerides ≥ 6.0 mmol/L * have a history of cancer, except non-melanoma skin cancer (basal cell, squamous cell) * have food allergies to study food components * have elevated blood pressure (\> 145/90) unless approved by GP * have acute or chronic infections (bacterial or viral) * have chronic inflammatory diseases (e.g. rheumatoid arthritis, lupus; ulcerative colitis) * have other conditions which in the opinion of any of the investigators would make them unsuitable for the study

Design outcomes

Primary

MeasureTime frame
change in HbA1cfrom prestudy and week 0, to end of treatment weeks 8, 10, and 12
serum lipidsfrom prestudy and week 0, to end of treatment weeks 8, 10, and 12

Secondary

MeasureTime frame
fasting glucosefrom prestudy and week 0, to end of treatment weeks 8, 10, and 12
change in weight, waist and hip circumferenceweeks 0, 12
blood pressurefrom prestudy and week 0, to end of treatment weeks 8, 10, and 12
creatine, urea, and c-peptides in 24 hour urine collection0, 12 weeks.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026